How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Identifieur interne : 002B03 ( PubMed/Checkpoint ); précédent : 002B02; suivant : 002B04How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Auteurs : Dorothée Obach [France] ; Yazdan Yazdanpanah [France] ; Gamal Esmat [Égypte] ; Anchalee Avihingsanon [Thaïlande] ; Sahar Dewedar [Égypte] ; Nicolas Durier [Thaïlande] ; Alain Attia [Côte d'Ivoire] ; Wagida A. Anwar [Égypte] ; Anthony Cousien [France] ; Pisit Tangkijvanich [Thaïlande] ; Serge Paul Eholié [Côte d'Ivoire] ; Wahid Doss [Égypte] ; Aya Mostafa [Égypte] ; Arnaud Fontanet [France] ; Mostafa K. Mohamed [Égypte] ; Sylvie Deuffic-Burban [France]Source :
- Hepatology (Baltimore, Md.) [ 1527-3350 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Hépatite C.
- usage thérapeutique : Antiviraux.
- virologie : Cirrhose du foie.
- Analyse coût-bénéfice, Humains, Hépatite C, Modèles théoriques, Pays en voie de développement.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- complications : Hepatitis C.
- drug therapy : Hepatitis C.
- virology : Liver Cirrhosis.
- Cost-Benefit Analysis, Developing Countries, Humans, Models, Theoretical.
Abstract
In resource-constrained countries where the prevalence of hepatitis C virus (HCV) disease is usually high, it is important to know which population should be treated first in order to increase treatment effectiveness. The aim was to estimate the effectiveness of different HCV treatment eligibility scenarios in three different countries. Using a Markov model, we estimated the number of life-years saved (LYS) with different treatment eligibility scenarios according to fibrosis stage (F1-F4 or F3-4), compared to base case (F2-F4), at a constant treatment rate, of patients between 18 and 60 years of age, at stages F0/F1 to F4, without liver complications or coinfections, chronically infected by HCV, and treated with pegylated interferon (IFN)/ribavirin or more-efficacious therapies (i.e. IFN free). We conducted the analysis in Egypt (prevalence = 14.7%; 45,000 patients treated/year), Thailand (prevalence = 2.2%; 1,000 patients treated/year), and Côte d'Ivoire (prevalence = 3%; 150 patients treated/year). In Egypt, treating F1 patients in addition to ≥F2 patients (SE1 vs. SE0) decreased LYS by 3.9%. Focusing treatment only on F3-F4 patients increased LYS by 6.7% (SE2 vs. SE0). In Thailand and Côte d'Ivoire, focusing treatment only on F3-F4 patients increased LYS by 15.3% and 11.0%, respectively, compared to treating patients ≥F2 (ST0 and SC0, respectively). Treatment only for patients at stages F3-F4 with IFN-free therapies would increase LYS by 16.7% versus SE0 in Egypt, 22.0% versus ST0 in Thailand, and 13.1% versus SC0 in Côte d'Ivoire. In this study, we did not take into account the yearly new infections and the impact of treatment on HCV transmission.
DOI: 10.1002/hep.27691
PubMed: 25581111
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25581111Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.</title><author><name sortKey="Obach, Dorothee" sort="Obach, Dorothee" uniqKey="Obach D" first="Dorothée" last="Obach">Dorothée Obach</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Esmat, Gamal" sort="Esmat, Gamal" uniqKey="Esmat G" first="Gamal" last="Esmat">Gamal Esmat</name><affiliation wicri:level="1"><nlm:affiliation>Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Avihingsanon, Anchalee" sort="Avihingsanon, Anchalee" uniqKey="Avihingsanon A" first="Anchalee" last="Avihingsanon">Anchalee Avihingsanon</name><affiliation wicri:level="1"><nlm:affiliation>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Dewedar, Sahar" sort="Dewedar, Sahar" uniqKey="Dewedar S" first="Sahar" last="Dewedar">Sahar Dewedar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Durier, Nicolas" sort="Durier, Nicolas" uniqKey="Durier N" first="Nicolas" last="Durier">Nicolas Durier</name><affiliation wicri:level="1"><nlm:affiliation>TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Attia, Alain" sort="Attia, Alain" uniqKey="Attia A" first="Alain" last="Attia">Alain Attia</name><affiliation wicri:level="1"><nlm:affiliation>UFR des Sciences Médicales, Université Félix Houphouet Boigny de Cocody, Abidjan, Côte d'Ivoire.</nlm:affiliation><country xml:lang="fr">Côte d'Ivoire</country><wicri:regionArea>UFR des Sciences Médicales, Université Félix Houphouet Boigny de Cocody, Abidjan</wicri:regionArea><wicri:noRegion>Abidjan</wicri:noRegion></affiliation></author><author><name sortKey="Anwar, Wagida A" sort="Anwar, Wagida A" uniqKey="Anwar W" first="Wagida A" last="Anwar">Wagida A. Anwar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Cousien, Anthony" sort="Cousien, Anthony" uniqKey="Cousien A" first="Anthony" last="Cousien">Anthony Cousien</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Tangkijvanich, Pisit" sort="Tangkijvanich, Pisit" uniqKey="Tangkijvanich P" first="Pisit" last="Tangkijvanich">Pisit Tangkijvanich</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Eholie, Serge Paul" sort="Eholie, Serge Paul" uniqKey="Eholie S" first="Serge Paul" last="Eholié">Serge Paul Eholié</name><affiliation wicri:level="1"><nlm:affiliation>Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire.</nlm:affiliation><country xml:lang="fr">Côte d'Ivoire</country><wicri:regionArea>Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan</wicri:regionArea><wicri:noRegion>Abidjan</wicri:noRegion></affiliation></author><author><name sortKey="Doss, Wahid" sort="Doss, Wahid" uniqKey="Doss W" first="Wahid" last="Doss">Wahid Doss</name><affiliation wicri:level="1"><nlm:affiliation>National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>National Hepatology and Tropical Medicine Research Institute, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Mostafa, Aya" sort="Mostafa, Aya" uniqKey="Mostafa A" first="Aya" last="Mostafa">Aya Mostafa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Fontanet, Arnaud" sort="Fontanet, Arnaud" uniqKey="Fontanet A" first="Arnaud" last="Fontanet">Arnaud Fontanet</name><affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Emerging Disease Epidemiology Unit, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pasteur, Emerging Disease Epidemiology Unit, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mohamed, Mostafa K" sort="Mohamed, Mostafa K" uniqKey="Mohamed M" first="Mostafa K" last="Mohamed">Mostafa K. Mohamed</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Deuffic Burban, Sylvie" sort="Deuffic Burban, Sylvie" uniqKey="Deuffic Burban S" first="Sylvie" last="Deuffic-Burban">Sylvie Deuffic-Burban</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25581111</idno><idno type="pmid">25581111</idno><idno type="doi">10.1002/hep.27691</idno><idno type="wicri:Area/PubMed/Corpus">002C31</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C31</idno><idno type="wicri:Area/PubMed/Curation">002B58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B58</idno><idno type="wicri:Area/PubMed/Checkpoint">002B58</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002B58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.</title><author><name sortKey="Obach, Dorothee" sort="Obach, Dorothee" uniqKey="Obach D" first="Dorothée" last="Obach">Dorothée Obach</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Esmat, Gamal" sort="Esmat, Gamal" uniqKey="Esmat G" first="Gamal" last="Esmat">Gamal Esmat</name><affiliation wicri:level="1"><nlm:affiliation>Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Avihingsanon, Anchalee" sort="Avihingsanon, Anchalee" uniqKey="Avihingsanon A" first="Anchalee" last="Avihingsanon">Anchalee Avihingsanon</name><affiliation wicri:level="1"><nlm:affiliation>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Dewedar, Sahar" sort="Dewedar, Sahar" uniqKey="Dewedar S" first="Sahar" last="Dewedar">Sahar Dewedar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Durier, Nicolas" sort="Durier, Nicolas" uniqKey="Durier N" first="Nicolas" last="Durier">Nicolas Durier</name><affiliation wicri:level="1"><nlm:affiliation>TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Attia, Alain" sort="Attia, Alain" uniqKey="Attia A" first="Alain" last="Attia">Alain Attia</name><affiliation wicri:level="1"><nlm:affiliation>UFR des Sciences Médicales, Université Félix Houphouet Boigny de Cocody, Abidjan, Côte d'Ivoire.</nlm:affiliation><country xml:lang="fr">Côte d'Ivoire</country><wicri:regionArea>UFR des Sciences Médicales, Université Félix Houphouet Boigny de Cocody, Abidjan</wicri:regionArea><wicri:noRegion>Abidjan</wicri:noRegion></affiliation></author><author><name sortKey="Anwar, Wagida A" sort="Anwar, Wagida A" uniqKey="Anwar W" first="Wagida A" last="Anwar">Wagida A. Anwar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Cousien, Anthony" sort="Cousien, Anthony" uniqKey="Cousien A" first="Anthony" last="Cousien">Anthony Cousien</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Tangkijvanich, Pisit" sort="Tangkijvanich, Pisit" uniqKey="Tangkijvanich P" first="Pisit" last="Tangkijvanich">Pisit Tangkijvanich</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Eholie, Serge Paul" sort="Eholie, Serge Paul" uniqKey="Eholie S" first="Serge Paul" last="Eholié">Serge Paul Eholié</name><affiliation wicri:level="1"><nlm:affiliation>Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire.</nlm:affiliation><country xml:lang="fr">Côte d'Ivoire</country><wicri:regionArea>Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan</wicri:regionArea><wicri:noRegion>Abidjan</wicri:noRegion></affiliation></author><author><name sortKey="Doss, Wahid" sort="Doss, Wahid" uniqKey="Doss W" first="Wahid" last="Doss">Wahid Doss</name><affiliation wicri:level="1"><nlm:affiliation>National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>National Hepatology and Tropical Medicine Research Institute, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Mostafa, Aya" sort="Mostafa, Aya" uniqKey="Mostafa A" first="Aya" last="Mostafa">Aya Mostafa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Fontanet, Arnaud" sort="Fontanet, Arnaud" uniqKey="Fontanet A" first="Arnaud" last="Fontanet">Arnaud Fontanet</name><affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Emerging Disease Epidemiology Unit, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pasteur, Emerging Disease Epidemiology Unit, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mohamed, Mostafa K" sort="Mohamed, Mostafa K" uniqKey="Mohamed M" first="Mostafa K" last="Mohamed">Mostafa K. Mohamed</name><affiliation wicri:level="1"><nlm:affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo</wicri:regionArea><wicri:noRegion>Cairo</wicri:noRegion></affiliation></author><author><name sortKey="Deuffic Burban, Sylvie" sort="Deuffic Burban, Sylvie" uniqKey="Deuffic Burban S" first="Sylvie" last="Deuffic-Burban">Sylvie Deuffic-Burban</name><affiliation wicri:level="3"><nlm:affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Hepatology (Baltimore, Md.)</title><idno type="eISSN">1527-3350</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Cost-Benefit Analysis</term><term>Developing Countries</term><term>Hepatitis C (complications)</term><term>Hepatitis C (drug therapy)</term><term>Humans</term><term>Liver Cirrhosis (virology)</term><term>Models, Theoretical</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Antiviraux (usage thérapeutique)</term><term>Cirrhose du foie (virologie)</term><term>Humains</term><term>Hépatite C ()</term><term>Hépatite C (traitement médicamenteux)</term><term>Modèles théoriques</term><term>Pays en voie de développement</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Developing Countries</term><term>Humans</term><term>Models, Theoretical</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Humains</term><term>Hépatite C</term><term>Modèles théoriques</term><term>Pays en voie de développement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In resource-constrained countries where the prevalence of hepatitis C virus (HCV) disease is usually high, it is important to know which population should be treated first in order to increase treatment effectiveness. The aim was to estimate the effectiveness of different HCV treatment eligibility scenarios in three different countries. Using a Markov model, we estimated the number of life-years saved (LYS) with different treatment eligibility scenarios according to fibrosis stage (F1-F4 or F3-4), compared to base case (F2-F4), at a constant treatment rate, of patients between 18 and 60 years of age, at stages F0/F1 to F4, without liver complications or coinfections, chronically infected by HCV, and treated with pegylated interferon (IFN)/ribavirin or more-efficacious therapies (i.e. IFN free). We conducted the analysis in Egypt (prevalence = 14.7%; 45,000 patients treated/year), Thailand (prevalence = 2.2%; 1,000 patients treated/year), and Côte d'Ivoire (prevalence = 3%; 150 patients treated/year). In Egypt, treating F1 patients in addition to ≥F2 patients (SE1 vs. SE0) decreased LYS by 3.9%. Focusing treatment only on F3-F4 patients increased LYS by 6.7% (SE2 vs. SE0). In Thailand and Côte d'Ivoire, focusing treatment only on F3-F4 patients increased LYS by 15.3% and 11.0%, respectively, compared to treating patients ≥F2 (ST0 and SC0, respectively). Treatment only for patients at stages F3-F4 with IFN-free therapies would increase LYS by 16.7% versus SE0 in Egypt, 22.0% versus ST0 in Thailand, and 13.1% versus SC0 in Côte d'Ivoire. In this study, we did not take into account the yearly new infections and the impact of treatment on HCV transmission.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25581111</PMID><DateCreated><Year>2015</Year><Month>06</Month><Day>25</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2016</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3350</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Hepatology (Baltimore, Md.)</Title><ISOAbbreviation>Hepatology</ISOAbbreviation></Journal><ArticleTitle>How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.</ArticleTitle><Pagination><MedlinePgn>31-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.27691</ELocationID><Abstract><AbstractText Label="UNLABELLED">In resource-constrained countries where the prevalence of hepatitis C virus (HCV) disease is usually high, it is important to know which population should be treated first in order to increase treatment effectiveness. The aim was to estimate the effectiveness of different HCV treatment eligibility scenarios in three different countries. Using a Markov model, we estimated the number of life-years saved (LYS) with different treatment eligibility scenarios according to fibrosis stage (F1-F4 or F3-4), compared to base case (F2-F4), at a constant treatment rate, of patients between 18 and 60 years of age, at stages F0/F1 to F4, without liver complications or coinfections, chronically infected by HCV, and treated with pegylated interferon (IFN)/ribavirin or more-efficacious therapies (i.e. IFN free). We conducted the analysis in Egypt (prevalence = 14.7%; 45,000 patients treated/year), Thailand (prevalence = 2.2%; 1,000 patients treated/year), and Côte d'Ivoire (prevalence = 3%; 150 patients treated/year). In Egypt, treating F1 patients in addition to ≥F2 patients (SE1 vs. SE0) decreased LYS by 3.9%. Focusing treatment only on F3-F4 patients increased LYS by 6.7% (SE2 vs. SE0). In Thailand and Côte d'Ivoire, focusing treatment only on F3-F4 patients increased LYS by 15.3% and 11.0%, respectively, compared to treating patients ≥F2 (ST0 and SC0, respectively). Treatment only for patients at stages F3-F4 with IFN-free therapies would increase LYS by 16.7% versus SE0 in Egypt, 22.0% versus ST0 in Thailand, and 13.1% versus SC0 in Côte d'Ivoire. In this study, we did not take into account the yearly new infections and the impact of treatment on HCV transmission.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our model-based analysis demonstrates that prioritizing treatment in F3-F4 patients in resource-constrained countries is the most effective scenario in terms of LYS, regardless of treatment considered.</AbstractText><CopyrightInformation>© 2015 by the American Association for the Study of Liver Diseases.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Obach</LastName><ForeName>Dorothée</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdanpanah</LastName><ForeName>Yazdan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de maladies Infectieuses et tropicales, Hôpital Bichat Claude Bernard, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmat</LastName><ForeName>Gamal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avihingsanon</LastName><ForeName>Anchalee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy and Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewedar</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durier</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attia</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UFR des Sciences Médicales, Université Félix Houphouet Boigny de Cocody, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Médecine et d'Hépato-Gastroentérologie, CHU de Yopougon, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anwar</LastName><ForeName>Wagida A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cousien</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangkijvanich</LastName><ForeName>Pisit</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eholié</LastName><ForeName>Serge Paul</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Dermatologie-Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programme PAC-CI, ANRS, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doss</LastName><ForeName>Wahid</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mostafa</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontanet</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Emerging Disease Epidemiology Unit, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Conservatoire National des Arts et Métiers, Chaire Santé et Développement, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Mostafa K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deuffic-Burban</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Inserm UMR 1137, IAME, F-75018 Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U995, Université Lille Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hepatology</MedlineTA><NlmUniqueID>8302946</NlmUniqueID><ISSNLinking>0270-9139</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):193-4</RefSource><PMID Version="1">25708046</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Hepatology. 2015 Jul;62(1):13-5</RefSource><PMID Version="1">25820452</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25581111</ArticleId><ArticleId IdType="doi">10.1002/hep.27691</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Côte d'Ivoire</li><li>France</li><li>Thaïlande</li><li>Égypte</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Obach, Dorothee" sort="Obach, Dorothee" uniqKey="Obach D" first="Dorothée" last="Obach">Dorothée Obach</name></region><name sortKey="Cousien, Anthony" sort="Cousien, Anthony" uniqKey="Cousien A" first="Anthony" last="Cousien">Anthony Cousien</name><name sortKey="Deuffic Burban, Sylvie" sort="Deuffic Burban, Sylvie" uniqKey="Deuffic Burban S" first="Sylvie" last="Deuffic-Burban">Sylvie Deuffic-Burban</name><name sortKey="Fontanet, Arnaud" sort="Fontanet, Arnaud" uniqKey="Fontanet A" first="Arnaud" last="Fontanet">Arnaud Fontanet</name><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name></country><country name="Égypte"><noRegion><name sortKey="Esmat, Gamal" sort="Esmat, Gamal" uniqKey="Esmat G" first="Gamal" last="Esmat">Gamal Esmat</name></noRegion><name sortKey="Anwar, Wagida A" sort="Anwar, Wagida A" uniqKey="Anwar W" first="Wagida A" last="Anwar">Wagida A. Anwar</name><name sortKey="Dewedar, Sahar" sort="Dewedar, Sahar" uniqKey="Dewedar S" first="Sahar" last="Dewedar">Sahar Dewedar</name><name sortKey="Doss, Wahid" sort="Doss, Wahid" uniqKey="Doss W" first="Wahid" last="Doss">Wahid Doss</name><name sortKey="Mohamed, Mostafa K" sort="Mohamed, Mostafa K" uniqKey="Mohamed M" first="Mostafa K" last="Mohamed">Mostafa K. Mohamed</name><name sortKey="Mostafa, Aya" sort="Mostafa, Aya" uniqKey="Mostafa A" first="Aya" last="Mostafa">Aya Mostafa</name></country><country name="Thaïlande"><noRegion><name sortKey="Avihingsanon, Anchalee" sort="Avihingsanon, Anchalee" uniqKey="Avihingsanon A" first="Anchalee" last="Avihingsanon">Anchalee Avihingsanon</name></noRegion><name sortKey="Durier, Nicolas" sort="Durier, Nicolas" uniqKey="Durier N" first="Nicolas" last="Durier">Nicolas Durier</name><name sortKey="Tangkijvanich, Pisit" sort="Tangkijvanich, Pisit" uniqKey="Tangkijvanich P" first="Pisit" last="Tangkijvanich">Pisit Tangkijvanich</name></country><country name="Côte d'Ivoire"><noRegion><name sortKey="Attia, Alain" sort="Attia, Alain" uniqKey="Attia A" first="Alain" last="Attia">Alain Attia</name></noRegion><name sortKey="Eholie, Serge Paul" sort="Eholie, Serge Paul" uniqKey="Eholie S" first="Serge Paul" last="Eholié">Serge Paul Eholié</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002B03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25581111
|texte= How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25581111" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |